iBio Inc (NYSEMKT:IBIO) New Highs Coming

iBio Inc (NYSEMKT:IBIO) is a top play on the coronavirus and one which smart investors should have in their portfolio. The latest news on its coronavirus vaccine supports our thesis. As we take a further look, there's a lot to like with iBio Inc. iBio Inc Daily Chart

About iBio Inc

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas.Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products which include IBIO-100 for the treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine. For more information, visit www.ibioinc.com.[embed]https://www.youtube.com/watch?v=xBK9-mrBnS0&feature=emb_title[/embed]

iBio Inc COVID-19 Vaccine Program

Immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are proceeding at Texas A&M University System (“TAMUS”) laboratories. The work is being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016. Tom Isett, Co-Chairman & Chief Executive Officer of iBio, said:

“This next stage of work on IBIO-200 is critically important as we seek to quickly enter the clinic with one of our VLP candidates. As we optimize our choice of adjuvants with both VLP types we have developed, we are fortunate to have a strong relationship with TAMUS that allows us to rapidly bring their deep insight into the pathogenesis of coronaviruses and experience with vaccine development to the task.”

iBio created its proprietary VLP candidates in just a few weeks using its FastPharming System™. iBio’s researchers then deployed this plant-based expression platform’s rapid production capabilities to deliver VLPs suitable for further development just weeks after the biologics were designed. Dr. James Samuel, Head of the Department of Microbial Pathogenesis and Immunology at Texas A&M University, said:

“We see strong potential for the IBIO-200 program given that we have both the glycosylated and non-glycosylated iBio VLPs as options for development. We look forward to completing the preclinical immunization studies for iBio to determine the optimal combination of VLP and adjuvant to advance to human clinical trials.”

Cash Rich

iBio Inc has a deal with Lincoln Park Capital Fund, LLC, for the purchase of up to $50M of its common stock over a three-year period subject to conditions. This will give the company plenty of cash to fund operations over the next three years. Cash is the biggest concern for small biotechs and that's no longer a concern for iBio Inc.

Bottom Line

Coronavirus is here to stay until a vaccine is commercialized. iBio Inc is at the forefront of a vaccine and one of the best plays for investors on a pandemic the modern world has never seen before. If iBio Inc succeeds, it will solve a major humanitarian crisis and shareholders will have banked big profits. Good luck to all!We will be updating our subscribers on the latest coronavirus stock plays. Sign up today!Disclosure: We have NO position in NYSEMKT:IBIO and have NOT been compensated for this article.Image by Miguel Á. Padriñán from Pixabay